NEUROSENSE THERAPEUTICS LTD (NRSN)
IL0011809592 - Common Stock
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases...
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases,...
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases,...
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a company developing novel treatments for severe neurodegenerative...
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
/PRNewswire/ -- Lonza (SIX: LONN), a global development and manufacturing partner to the pharma, biotech and nutrition industries, and NeuroSense Therapeutics...
NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023
NRSN stock results show that NeuroSense Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips NeuroSense Therapeutics (NASDAQ:NRSN) just reported results for the fourth quar...
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning!
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, shares a...
NeuroSense Therapeutics gets notice from Nasdaq (NASDAQ:NRSN)
NeuroSense Therapeutics receives notice from Nasdaq regarding failure to meet minimum stockholders' equity requirement.
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a company developing treatments for severe neurodegenerative...
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
A statistically significant, 37.4% difference (P=0.03), slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers for Wednesday with a breakdown of all the latest news this morning!
NeuroSense ALS candidate meets key study goals (NASDAQ:NRSN)
NeuroSense's lead drug candidate, PrimeC, achieves primary safety and tolerability endpoints in a Phase 2b ALS trial, showing potential for disease...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers as we check out all of the hottest trading news for Tuesday morning!
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for neurodegenerative diseases, today announced it...
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...
NeuroSense CEO Provides Q3 2023 Update
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...
NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model
In collaboration with the University of Southern California's Ichida Stem Cell Lab, PrimeC was shown to significantly increase survival rate of induced motor...
NeuroSense ends equity offering, says it's fully funded into Q2 2024 (NRSN)
NeuroSense terminates its equity offering program, with the company now fully funded into Q2 2024 and past the anticipated release of Phase 2b data for its ALS drug PrimeC.
NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...
European Medicines Agency Grants NeuroSense SME Status
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced...
NeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...
NeuroSense CEO Provides Q2 2023 Update
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...
NeuroSense Therapeutics prices $4.5M stock and warrants offering (NASDAQ:NRSN)
NeuroSense Therapeutics (NRSN) priced a public offering of common shares and a concurrent private placement of warrants to raise $4.5 million, the company said Thursday
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...
NeuroSense stock rises on deal with Biogen for ALS drug (NASDAQ:NRSN)
NeuroSense Therapeutics (NRSN) announced a deal with Biogen (BIIB) on Tuesday to run a biomarker study to evaluate its lead asset PrimeC in ALS. Read more here.